Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
03 nov. 2023 09h15 HE
|
Theralink Technologies, Inc.
Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein...
Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results
11 sept. 2023 09h00 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
Standard Lithium Reports Fiscal Second Quarter 2023 Results, Furthers Progress on Path Toward Commercial Development
09 févr. 2023 10h04 HE
|
Standard Lithium
VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...
Interim Results for the six months ended 31 December 2021
03 mars 2022 07h00 HE
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two...
Interim results for the six months ended 30 June 2021
30 sept. 2021 07h00 HE
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST ...
Interim results for the six months ended 30 June 2021
30 sept. 2021 02h01 HE
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST ...
Synairgen plc - Interim results for the six months ended 30 June 2020
29 sept. 2020 07h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2020 Southampton, UK – 29 September 2020: Synairgen plc (LSE: SNG), the respiratory drug...
Ergomed plc Interim results for the six months ended 30 June 2020
22 sept. 2020 07h00 HE
|
Ergomed plc
PRESS RELEASE Interim results for the six months ended 30 June 2020 Services strategy drives revenue and profit growthOrder book growth underpins high forward visibility Total revenue growth of...
Vectura Group plc - 2020 Interim Results
15 sept. 2020 07h00 HE
|
Vectura Group plc
2020 Interim Results - Vectura reports 2020 financial performance on-track and demonstrates progress on strategy execution with 12 new CDMO deals signed year to date - Chippenham, UK – 15...
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
03 sept. 2020 08h30 HE
|
Auris Medical AG
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trialImprovement 1.9 to 2.4 times greater with highest dose than with placeboTrial to proceed with Part B to test AM-125...